Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis

Dustin Le, Mark Kilpatrick, Walter K. Kraft, Morgan E. Grams, Bernard G. Jaar, Jung-Im Shin · 2026

Read Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis by Dustin Le, Mark Kilpatrick, Walter K. Kraft, Morgan E. Grams, Bernard G. Jaar, Jung-Im Shin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13315691.txt.

Description

Dustin Le and colleagues emulate, in a 2026 target trial, a comparison of two diabetes drug classes in hemodialysis patients. Whether GLP-1 agonists beat DPP-4 inhibitors in dialysis was unknown, since dialysis patients were excluded from trials. Using 2011 to 2021 United States Renal Data System and Medicare claims, the team compared new users. The groups held 3,671 on GLP-1 drugs and 12,039 on DPP-4 drugs, all surviving at least 90 days on in-center hemodialysis before starting medication.

In intention-to-treat analysis, all-cause mortality showed no advantage for GLP-1 drugs, hazard ratio 0.98. Cardiovascular and infection mortality also showed no clear difference. In per-protocol analysis, censoring at discontinuation, the all-cause mortality hazard ratio fell to 0.81 favoring GLP-1 drugs. But discontinuation itself was common: 53 percent for GLP-1 drugs versus 42 percent for DPP-4 drugs at one year. The authors conclude continuous use may help survival, yet stopping the drugs limits their actual potential.

Catalog record

CREATORDustin Le, Mark Kilpatrick, Walter K. Kraft, Morgan E. Grams, Bernard G. Jaar, Jung-Im Shin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13315691

Browse the full library · About the Tower of Babel